44.08
-1.77(-3.86%)
Currency In USD
| Previous Close | 45.85 |
| Open | 45.32 |
| Day High | 45.94 |
| Day Low | 43.71 |
| 52-Week High | 58.4 |
| 52-Week Low | 17.86 |
| Volume | 257,925 |
| Average Volume | 1.33M |
| Market Cap | 3.51B |
| PE | -11.75 |
| EPS | -3.75 |
| Moving Average 50 Days | 41.1 |
| Moving Average 200 Days | 30.6 |
| Change | -1.77 |
If you invested $1000 in Akero Therapeutics, Inc. (AKRO) since IPO date, it would be worth $2,502.73 as of March 13, 2025 at a share price of $45.85. Whereas If you bought $1000 worth of Akero Therapeutics, Inc. (AKRO) shares 5 years ago, it would be worth $2,413.16 as of March 13, 2025 at a share price of $45.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 30, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, a
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 29, 2025 2:30 AM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, a
Akero Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Jan 27, 2025 9:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, a